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Abstract: Chemo-radiation is considered the standard procedure for
the management of limited disease small-cell lung cancer (SCLC).
Controversy remains as to when surgery should be considered. We
sought to determine the survival after complete resection of SCLC
and the prognostic impact of clinical and pathologic stage.
Methods: A retrospective review was undertaken of patients who
underwent surgery between 1980 and 2006. Patients were staged
according to the 6th edition of the Tumor, Node, Metastasis classifica-
tion of lung cancer, actuarial survival estimated with Kaplan Meier
methods and comparisons were undertaken using Cox regression.
Results: We identified 59 patients who underwent complete resec-
tion with nodal dissection for SCLC. The mean age (SD) was 62 (11)
years and 41 (69%) were men. Clinical staging information was
available in 53, listed by stage with IA (n  9), IB (n  21), IIA (n 
0), IIB (n  13), IIIA (n  9), IIIB (n  1). The median time to
follow-up (1st to 3rd quartile) was 2.8 (0.79–8.65) years with an overall
survival (95% confidence interval) at 1 and 5 years of 76% (65, 88),
52% (40, 68). There were no clear differences in the survival of patients
in clinical T categories (p 0.366) with good overall results in patients
across the spectrum of nodal disease from N0 to N2 (p  0.498).
Conclusions: This study shows excellent survival for stage I to III
patients who underwent lung resection with nodal dissection for
SCLC and supports the need to reevaluate surgery as primary
treatment and use of clinical Tumor, Node, Metastasis criteria in the
selection of patients with very limited disease for surgery.
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Combined modality therapy using chemotherapy and tho-racic irradiation is currently the standard of care for
limited-stage small cell lung carcinoma. However, cumula-
tive results from 25 years of North American chemo-radiation
trials reported a current median survival of 17 months 1 and
data from the Surveillance, Epidemiological and End Results
program of the National Cancer Institute (Bethesda, Mary-
land) reported an overall 5 year survival of 10%.2
Surgery has been considered unsuitable for patients
with limited stage disease as it had been associated with
overall 5 year survival of less than 5%.3 Early randomized
trials comparing surgery alone versus radiotherapy reported
4%4 survival at 2-years in patients randomized to surgery
alone and a 20% 2-year survival in patients randomized to
surgery after initial response to chemotherapy.5
The Veterans Administration staging is adequate in
clinical practice and trials of chemo-radiation. However,
limited stage disease (confined to the ipsilateral hemithorax)
constitutes a heterogeneous population. A refinement to the
staging has been proposed with a “very limited disease”
category assigned to patients with limited stage disease with-
out mediastinal nodal involvement.6
Some regard surgery as the appropriate treatment of a
peripheral small cell lung carcinoma without nodal involve-
ment7 or with very limited stage disease, but there remains
uncertainty if and when surgery best fits into the treatment
modality for limited-stage small cell lung carcinoma.
The aims of this study is to ascertain results of surgical
treatment and to evaluate the impact of stage on survival in
patients with completely resected very limited-stage sub-
group of patients with small cell lung cancer.
METHODS
A review was undertaken of patients who underwent
surgery for SCLC between 1980 and 2006 at the Royal
Brompton Hospital. Cases were identified from the pathology
archive up until 1999 and from a prospective lung cancer
resection database thereafter. All slides were reviewed by one
pathologist (AGN) and classified according to current histo-
logic criteria for neuroendocrine tumors. All patients under-
going surgery for small cell lung carcinoma underwent nodal
dissection.8 The standard workup for lung resection in the
1990 decade was computed tomography (CT) thorax and
routine mediastinoscopy and this changed in the 2000 decade
to CT thorax and routine integrated positron emission tomog-
raphy (PET)/CT scanning to assess for mediastinal (and
distant) disease with mediastinoscopy for patients with me-
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diastinal uptake. Clinical and pathologic staging was under-
taken according to the 6th edition of the TNM classification
of lung cancer.9 Patients within this group had been previ-
ously reported as a subgroup of neuroendocrine tumors.10
After consultation with our institutional review board
chairman, it was deemed that this study fulfilled the criteria
for a “service evaluation” as defined with the National Re-
search Ethics Service and it presented no ethical issue and did
not require formal research ethics committee review.
Data Acquisition
Individual patient data were collated from a prospective
histopathology database, patients case notes and autopsy reports.
Mortality was determined using the National Health Service
strategic tracing system (National Health Service, United King-
dom) and survivors contacted by telephone for interview.
Statistical Analysis
Categorical data are presented as frequency (%) and
continuous data as mean with standard deviation (SD) or
median with 1st and 3rd quartile. Probabilities of survival
were estimated using the Kaplan-Meier method. Cox propor-
tional hazards regression models were used to ascertain the
association between individual factors and survival.
RESULTS
From January 1, 1980 to January 1, 2007, a total of 59
patients underwent complete R(0) resection for small cell
lung carcinoma. The diagnosis of SCLC was known preop-
eratively in 20 patients, 10 of whom had nodal disease (7
cN1, 3 cN2). No patient in this series had any documentation
of preoperative chemotherapy. The mean age (SD) was 62
(11) years and 41 (70%) were men. The pathologic subtype
was pure small cell lung carcinoma in 43 (73%) of patients
and small cell in combination with another tumor type in the
remaining 16 cases. Clinical and post surgical pathologic
staging information was available in 53 and 55 patients
respectively. In total, 21 patients underwent mediastinoscopy
and lymph node biopsies, of which 4 were positive for N2
disease. Baseline characteristics, stage and operation extent
are summarized in Table 1. Postoperatively, it was docu-
mented that 13 patients had received adjuvant chemotherapy,
2 patients received adjuvant radiotherapy, and 1 patient
received adjuvant chemo-radiotherapy.
The median time to follow-up (1st to 3rd quartile) was
2.8 (0.79–8.65) years with an overall survival (95% confi-
dence interval) at 1 and 5 years of 76% (65, 88) and 52% (40,
FIGURE 1. Overall survival (95% confidence interval) after
lung resection for small cell lung cancer. Numbers at risk are
presented per year.
TABLE 1. Baseline Characteristics
Number 59
Mean age, years (SD) 62 (11)
Men, n (%) 41 (69)
Pathology
Pure small cell, n (%) 43 (73)
Small cell and LCNEC, n (%) 8 (14)
Small cell and other combination, n (%) 8 (14)
Clinical Pathologic
T category
N/Aa 6 (10) 2 (3)
T1 11 (19) 15 (25)
T2 37 (63) 38 (64)
T3 6 (7) 3 (5)
T4 1 (2) 1 (2)
Clinical Pathologic
N category
N/Aa 6 (10) 4 (7)
N0 31 (53) 18 (31)
N1 15 (25) 21 (36)
N2 7 (12) 16 (27)
Clinical Pathologic
Stage
N/Aa 6 (10) 4 (7)
IA 9 (15) 5 (8)
IB 21 (36) 11 (19)
IIA 0 (0) 4 (7)
IIB 13 (22) 18 (31)
IIIA 9 (15) 16 (27)
IIIB 1 (2) 1 (2)
Operation, n (%)
Pneumonectomy 26 (44)
Lobectomy 26 (44)
Bilobectomy 4 (7)
Non anatomical 2 (3)
Not documented 1 (2)
a N/A, Insufficient detail available for classification.
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68), respectively (Figure 1). The disease free survival at 1 and
5 years was 76% (65, 88) and 46% (34, 62), respectively
(Figure 2).
There were no significant differences in the survival of
patients with pure small cell lung carcinoma and those with
small cell lung carcinoma in conjunction with another tumor
type (p  0.509). There was no difference in survival across
clinical T (p  0.366) or clinical N categories (p  0.489),
with good survival in all nodal categories after complete
resection (Figure 3). This resulted in poor discrimination of
survival in clinical Union Internationale Contre le Cancer
(UICC) stage grouping (p 0.650, Figure 4), with increasing
age as the only significant predictor of mortality after com-
plete surgical resection (Table 2).
The results were similar when analyzed using patho-
logic stage and no significant differences in survival were
noted across the pathologic T (p  0.331) or pathologic N
(p  0.597) categories.
FIGURE 2. Disease free survival (95% confidence interval)
after lung resection for small cell lung cancer. Numbers at
risk are presented per year.
FIGURE 3. Survival by clinical nodal status after complete
resection. Numbers at risk are presented per year.
FIGURE 4. Survival by UICC clinical stage grouping after
complete resection. Numbers at risk are presented per year.
TABLE 2. Univariable Risk Factors for Death
Hazard Ratio
95% Confidence
Interval p
Age, per decade increase 1.52 1.00–2.31 0.05
Female sex 0.68 0.27–1.69 0.41
Mixed pathology 1.34 0.56–3.20 0.51
T category
cT1 1.00 NA NA
cT2 2.28 0.67–7.70 0.19
cT3 or 4 1.79 0.30–10.80 0.52
N category
cN0 1.00 NA NA
cN1 0.49 0.24–1.62 0.33
cN2 0.58 0.17–2.02 0.40
Overall clinical stage
cI 1.00 NA NA
cII 0.84 0.32–2.18 0.71
cIII 0.60 0.20–1.82 0.36
NA, not applicable.
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DISCUSSION
From 2003–2005 we performed 267 lung resections for
non-small cell lung cancer and correspondingly, 6 procedures
for small cell lung cancer in this time frame. We estimate that
the lung resections performed for small cell lung cancer
comprises approximately 2% of our work load. In many
cases, the decision to operate was an active decision, based on
assessment of resectability of the primary tumor.
The results of our study reveal good survival in this
selected subgroup of patients in UICC stages I to III who
underwent lung resection of pure and combined small cell
lung carcinoma. In this series, there were no clear differences
in the outcome of patients across clinical and pathologic T
and N categories, and after surgical resection, UICC classi-
fication had a poor discriminatory value for prognosis.
Previous Trials
The role of surgery for the treatment of limited-stage
small cell lung carcinoma has been considered inappropriate
due to poor overall survival. The most widely cited support-
ing evidence of lack of benefit for surgical treatment was an
early Medical Research Council randomized trial of surgery
versus radiotherapy.4 Patients were recruited based on bron-
chial biopsies and complete resection was only achieved in 34
(48%) of patients, possibly reflecting the unavailability of CT
scanning and nonuse of mediastinoscopy in this trial, and
therefore the inclusion of patients not currently accepted to be
suitable for surgery. Analysis was performed by intention to
treat and therefore included the 37 patients who underwent
exploratory thoracotomy only or no surgery in the analysis of
the 71 patients in the surgical arm, undermining the conclu-
sion that the result of radical radiotherapy was “somewhat
better” than the result of “surgery.”
The second influential randomized trial was published
in 1994 in which patients who were diagnosed with SCLC on
bronchoscopy, where the origin of the tumor could be iden-
tified preoperatively and who responded to initial chemother-
apy were randomized to surgery or no additional treatment
with an overall 2 year-survival of 20% in both arms and a
study conclusion of no additional benefit of surgery.5 In this
study, 54/70 (77%) patients underwent complete resection
and again the intention to treat analysis included 8 patients
who refused surgery, 4 who had an incomplete resection, and
12 patients with unresectable disease. Although we do not
contend that an intention to treat analysis was inappropriate,
the failure to adhere to protocol renders the results of inten-
tion to treat analysis susceptible to bias. What is perhaps most
difficult with trials that evaluate surgery as an adjuvant
treatment modality is the conundrum that the surgeon faces at
thoracotomy, to resect a clearance margin based on the
operative findings, or a margin based on prechemotherapy
defined disease. After all, the surgeon is not able to visualize
the presence of microscopic residual disease that may be
present after chemotherapy.
The pendulum of opinion may have swung too far
against surgical treatment as an option in SCLC and it has
become difficult for surgeons to justify the routine resection
of limited stage small cell lung carcinoma patients based on
the results of these two influential randomized trials. Some
clinicians might even consider surgery inappropriate for pa-
tients who present with solitary pulmonary nodules that prove
to be small cell lung cancer on fine needle aspiration biopsy.
Our surgical series suggests that good results can be
achieved in selected patients with complete resection
throughout the spectrum of UICC stage I to III. The results do
not suggest that we should routinely operate upon all patients
in stage I to III. However, the overall 5 year survival of 52%
in our series does suggest the need for further randomized
trials to clarify appropriate case selection for surgery in light
of improved staging modalities (spiral CT, PET, magnetic
resonance imaging, transthoracic needle aspiration biopsy,
endoscopic esophageal ultrasound guided biopsy, and endo-
scopic transbronchial ultrasound guided biopsy). Perhaps the
most influential of which has been PET with the ability to
evaluate local, mediastinal and distant disease, certainly in
the non-small cell setting.11,12
Clinical Staging
The currently accepted Veterans Administration stag-
ing criteria remains adequate when evaluating more extensive
cases for chemotherapy and radiotherapy. Shepherd et al. 6
suggested a refinement to the Veterans Administration stag-
ing by introducing the “very limited” category in patients
without evidence of mediastinal nodal disease. However, if
surgery is to be considered as a treatment modality a more
detailed clinical staging classification needs to be adopted,
perhaps the most useful would be the TNM classification of
lung cancer; it encompasses the subcategory of “limited”
disease in the N2 designation and also allows the assessment
of the extent of surgery required (T category). The N2
designation has traditionally been considered as a contrain-
dication to surgery. While in this series, there were 3/7 and
6/16 patients on follow-up identified to have N2 disease on
clinical and pathologic staging respectively these numbers are
too small to offer definitive conclusions on patient selection.
This underscores the heterogeneity of the spectrum of N2
designation ranging from bulky mediastinal node disease to
occult metastasis identified only on histologic analysis of
resected lymph nodes, and the need to avoid a blanket
exclusion of the N2 subgroup from the possible beneficial
effects of surgical resection.
Pathologic Staging
Clinical staging is often applied to guide management
and pathologic staging to predict prognosis, although the two
aims are often not mutually exclusive. In our series, the
influence of nodal involvement was unclear; the best prog-
nostic subgroup was in patients with N2 disease, as a result
when the UICC stage grouping was applied, no clear discrim-
ination in survival was obtained. This applied to both clinical
and pathologic N categories. Adjuvant chemotherapy has
been more rigorously evaluated in non-small cell cancer
setting with meta-analysis of randomized trials reporting a
13% relative reduction in the hazard for death,13 but less
information is known in the small cell setting with some
centers opting for routine adjuvant chemotherapy.3
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Potential Limitations
We are aware of the limitations of our sample as only
26 deaths were experienced in our series, and the power of a
survival analyses are derived from the number of events
rather than the sample size. Our report may represent a
chance finding of long term survival in our cohort. Another
point of view is that the determinants of prognosis in com-
pletely resected small cell lung cancer are incompletely
understood and patients with advanced stage (stage III) dis-
ease actually had long term survival. We accept that we have
no information on open-and-close cases for SCLC during this
time, nor did we have robust information on adjuvant treat-
ment for inclusion in this study. Our institution is a tertiary
referral center and many treated patients return to the care of
their local oncologists, outside our catchment area.
CONCLUSIONS
With careful case selection, good results can be ob-
tained for patients undergoing lung resection for limited
disease small cell lung cancer when complete resection can
be achieved. Randomized trials are required to assess the
effects of surgery as part of multimodality treatment in the
presence of improved staging modalities. More work is re-
quired to improve on existing clinical classification models
for patients who are potentially suitable for surgery and to
develop better prognostic models in patients who have un-
dergone complete resection for small cell lung cancer.
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